Markets
Borrow
Earn
Invest
Pro
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Pro
Roxom Pro
The keyboard terminal for every market.
Charts
Our charting engine, in dollars, bitcoin or sats.
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CE
CEP
CE
CEP
CEP
News
·
Immatics Announces $125 Million Underwritten Offering
Mkt Cap
N/A
Volume
N/A
Next Earnings
N/A
Chart
Earnings
News
About
Insider
Filings
Immatics Announces $125 Million Underwritten Offering
Immatics N.V. plans to sell 12.5 million ordinary shares at $10.00 per share, expecting to raise $125 million in a public offering managed by Jefferies, Leerink Partners, and Cantor.
GlobeNewswire Inc. · Dec 5, 2025
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
Inhibikase Therapeutics is conducting a public offering of common stock and pre-funded warrants, raising approximately $100 million to support its clinical-stage pharmaceutical development for pulmonary arterial hypertension.
GlobeNewswire Inc. · Nov 21, 2025
Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants
Invivyd is conducting a public offering of 44 million common stock shares and 6 million pre-funded warrants at $2.50 per share, expecting to raise approximately $125 million to fund commercial preparedness, research and development, and corporate purposes.
GlobeNewswire Inc. · Nov 18, 2025
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
Disc Medicine has priced a public offering of common stock and pre-funded warrants, expecting to raise approximately $225 million to support potential drug commercialization and research efforts.
Benzinga · Oct 21, 2025
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
Disc Medicine has priced a public offering of common stock and pre-funded warrants, expecting to raise approximately $225 million to support potential commercialization of bitopertin and fund research and development.
GlobeNewswire Inc. · Oct 21, 2025
Zealand Pharma to participate in upcoming investor conferences in September 2025
Zealand Pharma will participate in multiple healthcare investor conferences in September 2025, with key executives hosting meetings and participating in fireside chats across events in Zürich, New York, Boston, London, and Brussels.
GlobeNewswire Inc. · Aug 28, 2025
Compass Therapeutics to Participate in Upcoming September Investor Events
Compass Therapeutics will participate in multiple healthcare and investment conferences in September 2025, including events in Boston and New York, presenting their oncology-focused antibody-based therapeutics research.
GlobeNewswire Inc. · Aug 26, 2025
Trump Insiders Want A Piece Of Crypto, SPAC Action: Is A Merger Coming?
Two executives with ties to Donald Trump and Trump Media & Technology Group have launched a SPAC targeting the cryptocurrency sector, which could attract investor attention given recent crypto-related merger announcements that have seen shares soar.
Benzinga · May 15, 2025
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
Tevogen CEO Dr. Ryan Saadi will participate in a panel discussion on strategies for adapting to market volatility at the BioNJ Bio Partnering Conference, along with experts from J.P. Morgan, RSM, and Cantor Fitzgerald.
GlobeNewswire Inc. · Apr 14, 2025
Why Rocket Lab Stock Is Sinking Today
Rocket Lab stock is down 5.3% after a 28% surge the previous day, as Cathie Wood's Ark Invest firm takes some profits. However, analysts remain bullish, with Cantor Fitzgerald and Bank of America raising their price targets on the stock.
The Motley Fool · Nov 14, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
CE
CEP
CEP
Buy
Sell
Market
Limit
Soon
CEP
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any CEP yet.
Related Tickers
Earnings